Bausch + Lomb Corporation (BLCO) Company Overview

Bausch + Lomb Corporation is a global eye-health company listed on the New York and Toronto stock exchanges under BLCO. Its products cover vision correction, eye comfort, prescription treatment, diagnostic preparation and ophthalmic surgery. Its official investor-relations site describes a mission of helping people see better to live better across every phase of life.

Which reporting segments define the company?

The FY2025 Form 10-K organizes operations into three reportable segments. Vision Care includes contact lenses, lens-care solutions, over-the-counter drops and vitamins. Pharmaceuticals includes branded and generic medicines for dry eye, glaucoma, inflammation, ocular hypertension, post-operative care and retinal disease. Surgical supplies equipment, intraocular lenses, delivery systems, consumables and instruments used in cataract, corneal, vitreous and retinal procedures.

Why does the company matter in eye health?

Bausch + Lomb can meet the same patient through lenses, consumer products, prescriptions, diagnostics and surgery. That breadth matters because retail merchandising, practitioner recommendation, prescribing and surgeon adoption require different capabilities. The company has each channel, although their margins and risks differ.

Almost all revenue comes from physical products; licensing, co-promotion and contract services were immaterial in FY2025. This is a branded-product and medical-device model. Revenue is generally recognized when control transfers, while certain intraocular lenses are recognized when consigned units are used.

Which segment is the biggest revenue source?

How does a sale become recurring revenue?

Repeat consumption is the attraction: lenses are replaced, drops and vitamins replenished, prescriptions refilled, and surgical systems pull through packs or implants. Each channel also applies pressure through retailer promotion, payer deductions or hospital purchasing discipline.

Where did the growth come from?

The latest official period is the quarter ended March 31, 2026; second-quarter results were scheduled for July 29 and were not yet reported. The Q1 2026 earnings release showed a $107 million revenue increase. Foreign exchange added $42 million, while price, volume and momentum in MIEBO, XIIDRA, premium lenses, daily silicone-hydrogel lenses and consumer eye care also contributed.

Did segment profitability improve?

The Q1 2026 Form 10-Q also shows that cost of goods sold fell to 38.9% of product sales from 42.5% a year earlier. That margin movement, together with lower selling, general and administrative expense, explains why operating income turned positive. R&D rose to $101 million, indicating that the improvement did not come from simply suppressing pipeline investment.

The relevant history is the shift from a venerable optical brand to a public, portfolio-wide eye-health platform with more pharmaceutical exposure and a heavier balance sheet.

1. 1853
   The company was founded, creating the long-lived name recognition that still supports consumer trust, professional familiarity and global distribution.
2. 2022
   BLCO common shares began trading on the NYSE and TSX. The IPO created a separately valued public entity, although Bausch Health retained controlling ownership.
3. 2023
   AcuFocus expanded premium cataract technology, while MIEBO launched in the United States and Bausch + Lomb agreed to acquire XIIDRA. The dry-eye strategy moved from a collection of products toward a broader disease-management franchise.
4. 2024
   The Trukera Medical acquisition added tear-osmolarity diagnostics and linked ocular-surface preparation more closely to surgical outcomes.
5. 2025
   Whitecap Biosciences added clinical-stage glaucoma and geographic-atrophy programs. The enVista recall simultaneously demonstrated how product quality can interrupt growth and compress Surgical profitability.
6. 2025 Investor Day
   Management formalized a three-year plan centered on above-market revenue growth, manufacturing and commercial efficiency, pipeline productivity and deleveraging.
7. Q1 2026
   Revenue growth, positive operating income and stronger adjusted EBITDA provided early evidence that portfolio growth and operational repair were beginning to show in reported results.

What did the XIIDRA transaction change?

The 2023 XIIDRA agreement was the largest recent pivot. The official announcement described a $1.75 billion upfront cash price financed with new debt. XIIDRA complements MIEBO and consumer dry-eye products, increasing pharmaceutical scale and margin potential while making deleveraging essential.

Where are the strongest competitive resources?

Vision Care benefits from repeat use, familiarity and practitioner fitting. Pharmaceuticals depends on prescriber adoption, reimbursement, evidence and intellectual property. Surgical creates workflow friction: trained surgeons and installed equipment can pull through compatible consumables and implants. Reproducing all three channels is difficult.

Who are the main competitors?

Competition is category-specific. Alcon is the closest broad rival; CooperVision is a major contact-lens specialist; Johnson & Johnson Vision competes in contacts and intraocular lenses; and AbbVie or generic entrants challenge individual drugs. Bausch + Lomb offers wider consumer-to-surgical coverage, while rivals may be stronger in a particular category.

In a Five Forces reading, rivalry is high and buyer power varies by channel. Retailers, payers and hospital systems negotiate aggressively. Clinical, regulatory and professional-adoption barriers protect prescriptions and surgery more than consumer categories, making the moat meaningful but uneven.

What does the annual baseline reveal?

FY2025 was mixed: revenue reached $5.101 billion, operating income was $113 million and the attributable net loss was $360 million. R&D totaled $371 million. Manufacturing pressure, recall effects, amortization, transformation costs and financing expense separated top-line growth from GAAP earnings, while free cash flow after investment remained weak.

Why are debt and interest the key constraint?

At March 31, 2026, gross debt was about $5.094 billion. Q1 operating income remained below interest expense, so stronger adjusted EBITDA had not produced comfortable GAAP coverage. Valuation therefore depends on margin expansion, cash conversion and debt reduction; leverage magnifies small operating changes for equity holders.

Bausch + Lomb is publicly traded but not widely controlled. As of April 22, 2026, Bausch Health Companies held 310,449,643 common shares, approximately 87% of issued and outstanding BLCO shares. The remainder is the public minority. This structure changes how investors should interpret governance, liquidity and potential corporate actions.

How does the parent stake affect governance?

The controlling stake links BLCO to the parent's separation plans and capital priorities, reduces the effective public float and limits outside institutions' influence. The 2025 proxy statement details the governance framework; the current 10-Q updates the holding.

What did the latest shareholder vote indicate?

The 2026 annual-meeting Form 8-K shows that all ten nominees were elected, executive compensation received advisory approval and PricewaterhouseCoopers was appointed auditor. The results demonstrate formal shareholder support, but the voting totals must be read in light of Bausch Health's dominant stake.

What are the most credible growth drivers?

The strongest near-term opportunity is ocular surface. MIEBO and XIIDRA address different dry-eye mechanisms, while consumer drops and Trukera diagnostics broaden the ecosystem. Daily silicone-hydrogel lenses add another driver as replacement frequency, comfort and convenience support premium mix.

Surgical recovery matters if premium lenses and consumables regain reliable supply and repeat use. Manufacturing capacity and sourcing improvements are intended to support margins. The 2025 Investor Day plan targeted about 50% adjusted cash conversion and net leverage near 3.5 times by the end of 2028.

The risks are interconnected. Product-quality problems can reduce revenue and confidence; patent loss can invite competition; and manufacturing disruption can weaken margin when leverage requires cash. Commercial growth must be matched by operational reliability.

Which risk is most important?

Leverage amplifies product, pricing and manufacturing setbacks because interest absorbs operating profit. Margin expansion and cash conversion can reverse that effect through debt reduction. The decisive measure is cash after capex, interest and working capital, not revenue or adjusted EBITDA alone.

A useful valuation model separates revenue growth, operating economics, reinvestment and financing. Segment-specific assumptions matter: Pharmaceuticals may grow faster, Vision Care supplies steadier scale, and Surgical offers margin upside if profitability normalizes.

How should valuation scenarios differ?

The key sensitivity is operating margin versus net leverage. Growth that remains absorbed by capex, working capital and interest creates limited equity benefit; higher margins plus cash conversion can add value through debt reduction.

Bausch + Lomb combines a well-known eye-care name with consumer products, contact lenses, prescriptions, diagnostics and surgery. That breadth creates repeat purchases, cross-channel relationships and exposure to dry eye, premium vision correction and surgical demand.

Q1 2026 supplied the strongest evidence: broad revenue growth, faster Pharmaceuticals, positive Surgical segment profit, better cost ratios and positive operating cash flow. Continued R&D spending suggests the improvement was not based only on cost cutting.

The constraint is acquisition-related debt, which makes interest, free cash flow and refinancing central. Leverage amplifies product-quality, patent and payer setbacks. Bausch Health's controlling stake also leaves public investors with minority economics and limited strategic influence.